New dual therapy shows success when treating metastatic prostate cancer

Поделиться
HTML-код
  • Опубликовано: 20 ноя 2023
  • The FDA has approved a new initial treatment for some metastatic prostate cancers.

Комментарии • 2

  • @EnestoJames
    @EnestoJames 5 месяцев назад +1

    must say that I have enormous respect for you
    Dr kanayo Peterson considering the manner in which my wife receive her complete treatment for
    HIV infection and cancer, thanks for coming to my rescue sir.

  • @DCGreenZone
    @DCGreenZone 5 месяцев назад

    Keep an eye on this, it seems miraculous.
    >>Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity’s 67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical response to treatment and an indicator of the recurrence of disease for prostate cancer.